Navigation Links
U.S. FDA Grants Priority Review to Bayer's Radium Ra 223 Dichloride NDA for Castration-Resistant Prostate Cancer with Bone Metastases
Date:2/12/2013

an Medicines Agency (EMA), or other health authorities. Bayer has submitted a Marketing Authorization Application to the EMA for radium-223 in December 2012 for the treatment of CRPC patients with bone metastases.

In January 2013, the U.S. Nuclear Regulatory Commission (NRC) issued a licensing decision on the medical use of radium-223. The decision states that U.S. medical sites will be able to procure and administer radium-223 under 10 CFR Part 35, Subpart E, which includes 10 CFR section 35.300.

About CRPC and Bone Metastases

Prostate cancer is the most common cancer among men in the United States (other than skin cancer).(1) Approximately 16% of prostate cancer cases are considered regional or distant, which means that the cancer has spread beyond the prostate to nearby or distant areas of the body (metastasis).(2)

A majority of men with CRPC have radiological evidence of bone metastases.(3)  Bone metastases secondary to prostate cancer typically target the lumbar spine, vertebrae and pelvis.(4)  In fact, bone metastases are the main cause of morbidity and death in patients with CRPC.(5)

About Oncology at Bayer

Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. Bayer's oncology franchise now includes two oncology products and several other compounds in various stages of clinical development. Together, these products reflect the company's approach to research, which prioritizes novel targets and pathways with the potential to transform the way that cancer is treated across tumor types and stages of disease.

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's leading, innovative companies in the healthcare a
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Afraxis Grants Exclusive Global License to Genentech
2. FDA Grants Soligenix Fast Track Designation for OrbeShield(TM) for the Reduction of Mortality Associated with Gastrointestinal Acute Radiation Syndrome (GI ARS)
3. New Jersey Health Foundation Awards First Two Innovation Stage Funding Grants
4. Artemis Diagnostics awarded two grants from Technology Strategy Board to develop cancer imaging technology
5. New Jersey Health Foundation Commits $2 Million to Fund Grants
6. FDA Grants Orphan Drug Status To Morphoteks Amatuximab (MORAb-009)
7. FDA Grants Soligenix Fast Track Designation for SGX203 for the Treatment of Pediatric Crohns Disease
8. ViiV Healthcare commits nearly £4M in Positive Action for Children Fund grants for programmes focused on alleviating burden of HIV on women and children
9. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
10. As Global Telemedicine Market Reaches $2.5 Billion, Industry Leaders Gather in San Diego to Discuss Grants, Funding, Vendor Selection, Credentialing, and More
11. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According ... on medical technology market intelligence, the ... and occlusion (TEO) device markets will expand moderately ... the fastest-growing segments. In particular, increasing interest in ... oncology has fueled rapid growth of these markets. ...
(Date:1/15/2014)... Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ... per share, net to the seller in cash, without ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ... including reductions in body fat content and preserved ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Inc. (Nasdaq: ALXA ) today announced that company ... will present during the MDB Bright Lights Conference 2011.  The ... 10:00 a.m. Eastern Time.  The presentation will be webcast live ... via the Web, please go to the Investor Relations tab ...
... DIEGO, May 6, 2011 Arena Pharmaceuticals, Inc. (NASDAQ: ... to present at the Bank of America Merrill Lynch 2011 Health ... Time (1:00 p.m. Eastern Time) at the Encore at the Wynn ... Ph.D., Arena,s Vice President, Lorcaserin Development, is scheduled to provide a ...
Cached Medicine Technology:Alexza to Present at the MDB Bright Lights Conference 2011 2Alexza to Present at the MDB Bright Lights Conference 2011 3Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference 2Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference 3
(Date:4/14/2014)... Therapeutics, Inc., announced today a publication demonstrating that ... human red blood cells exposed to plasma samples ... anemia (AIHA). The article entitled "TNT003, an inhibitor ... induced by cold agglutinin disease patient autoantibodies" was ... earlier this month. TNT003 is the murine analog ...
(Date:4/14/2014)... around the world, many people live and work in ... block sunlight. And as the global population continues to ... will only spread. , To alleviate the problem, ... redirects sunlight onto narrow streets and alleyways. The panel ... at an angle, where it spreads sunlight onto the ...
(Date:4/14/2014)... professor of chemical engineering at Virginia Tech , ... analyze living cells. The long-term goal is to gain ... In his lab , Lu and his students ... events inside cells. These devices promote high sensitivity and ... cells. , Based on their record of achievements, the ...
(Date:4/14/2014)... April 2014, Perth, Australia. Drug discovery company Proteomics ... development of a companion diagnostic (CDx) test with ... , The research team authenticated the panel of ... control samples. Seven biomarkers were validated at high ... , The mass spectrometry data was then cross-validated ...
(Date:4/14/2014)... guidelines for high-risk bladder cancer, chemotherapy before or ... clinical practice. The findings are published early online ... the American Cancer Society. , Clinical trials have ... muscle-invasive bladder cancer who are given chemotherapy before ... after surgery also improves survival. To investigate the ...
Breaking Medicine News(10 mins):Health News:Ex vivo efficacy of C1s antibody as Complement inhibitor in cold agglutinin disease 2Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2Health News:Efficient analysis of small quantity of cells improves chances to understand disease 2
... /PRNewswire/ -- Aesthetic Medical Educators ... medical professionals on Aesthetic Procedures over the past ... training include physicians, nurses, physician assistants and dentists, ... in his/her practice.These medical professionals have been trained ...
... Convene in Washington D.C. ... Pass Legislation that Will Protect the Public WASHINGTON, April ... of foodborne illness, including surviving family members of those ... Capitol to share their stories, meet with legislators and ...
... -- With the 2009 NBA playoff season ... public affairs television program that tells the compelling and ... and diabetes patient Dominique Wilkins. Sharing Miracles ... stations. A nine-time NBA all-star who spent the majority ...
... Controls Limit Vaccine SuppliesDALLAS, April 29 Fears of ... new vaccines, as well as meeting public demand for ... National Center for Policy Analysis. "We are facing ... six vaccines for common childhood illnesses," said NCPA Senior ...
... Executive Chairman & CEO Douglas MacLellan offers expert insight ... April 29 AMDL Inc. ... major operations in China, announced today its Executive Chairman ... featured in The Wall Street Transcript - ...
... appear to be safe, but more research needed ... shows promise in treating diabetic polyneuropathy, a disorder that ... years, a new study finds. , Researchers in Boston ... (VEGF) gene may help patients with diabetic polyneuropathy. The ...
Cached Medicine News:Health News:Aesthetic Medical Educators Training Successfully Trains Over 2,000 Medical Professionals on Aesthetic Procedures 2Health News:Foodborne Illness Victims Mark President Obama's First 100 Days By Calling For Permanent Fix To Food Safety System 2Health News:Foodborne Illness Victims Mark President Obama's First 100 Days By Calling For Permanent Fix To Food Safety System 3Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 2Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 3Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 4Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 5Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 6Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 7Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 8Health News:Swine Flu Outbreak Illustrates Problems in Vaccine Development 2Health News:Chinese Pharma Market Continues to Grow at a 5-7% Rate in 2009; AMDL Remains on Track to Meet FY09 Financial Targets 2Health News:Chinese Pharma Market Continues to Grow at a 5-7% Rate in 2009; AMDL Remains on Track to Meet FY09 Financial Targets 3Health News:Gene Therapy Improves Diabetic Neuropathy in Study 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: